BIA submission to NHSE consultation on the Innovative Medicines Fund

The BIA has responded to the NHS England consultation on proposals for the Innovative Medicines Fund (IMF)

In our submission, we highlighted:

• The potential impact that the IMF, if implemented correctly, could have in enabling greater and faster access to innovative medicines including for rare diseases.
• That the IMF should ensure alignment with the broader rare disease access landscape including with initiatives such as the NICE Methods and Processes Review and Rare Disease Framework.
• The BIA's concern that the proposals, as they stand, will fail to resolve the challenges faced by rare disease medicines associated with resolving uncertainty and demonstrating plausible cost-effectiveness.